Применение Глиатилина в стационарном лечении больных деменцией позднего возраста

Background. Observational studies take separate place in evaluation of the efficacy of modern therapy of old age dementias.The aim of the study was to investigate the results of use of Gliatilin for treatment of old age dementias under natural conditions of gerontopsychiatric practice within the framework of observational study.Material and methods. A total of 98 patients (63 males and 35 females; age median was 76 years) were examined by using non-selective method. The patients were hospitalized in psychogeriatric departments and they were treated with Gliatilin due to old age dementias (21 subjects with AD, 39 patients with mixed dementia, 37 cases with vascular dementia, and 1 patient with mild cognitive decline). In diagnostics and evaluation of the results of treatment with Gliatilin methods were used as follows: the clinical method, psychometric scales (MMSE, the clock drawing test), and Clinical global impression improvement scale. Gliatilin was prescribed in the form of intravenous infusions and per os within the framework of the course of anti-dementia treatment. The mean duration of treatment with Glitialin was equal to 4,7  3,4 months (M 5,0).Results. Improvement (moderate and minimal on Clinical global impression scale) in the state of patients during treatment with Gliatilin was noticed in 67,3% AD cases and in 86,7% VD cases. Clinical indices of improvement were confirmed with the increase of MMSE index on the average by 1 score in AD and by more than 2 scores in VD. Achievement of the improvement, or stabilization of state during treatment with Gliatilin of patients with dementias was possible at various degrees of its severity. Alongside with improvement of cognitive functioning reduction of psychopathological symptoms was detected, first of all, depressive and delirium- like confusion. During the treatment with Gliatilin no side effects of the drug were revealed.Conclusion. The use of Giatilin in the form of the course of intravenous infusions and per os is effective and safe in the treatment of Alzheimer’s disease, mixed dementias, and vascular dementia. The prescription of the drug at various degrees of dementia severity and in the presence of various non-cognitive disorders, including acute confusion states was substantiated.

поздний возраст, деменция, болезнь Альцгеймера, смешанная деменция, сосудистая деменция, лечение, Глиатилин, old age, dementia, Alzheimer’s disease, mixed dementia, vascular dementia, treatment, Gliatilin

1. Гаврилова С.И., Калын Я.Б., Михайлова Н.М. и др. Фармакоэкономические аспекты болезни Альцгеймера. Соврем. тер. в психиатр. и неврол. 2014;2:10-15. http:// logospress.ru/

2. Russ T.C., Stamatakis E., Hamer M. et al. Association between psychological distress and mortality: Individual participant pooled analysis of 10 prospective cohort studies. Br. Med. J. 2012;345. doi: 10.1136/bmj.e4933

3. Гаврилова С.И., Колыхалов И.В. Разработка стандарта терапии болезни Альцгеймера. Соврем. тер. в психиатр. и неврол. 2012;1:5-9. http://logospress.ru/

4. Curtin F., Schulz P. Assessing the benefit: risk ratio of a drug - randomized and naturalistic evidence. Dial. Clin. Neurosci. 2011;13(2):183-192

5. Leon A.C. Evaluation of psychiatric interventions in an observational study: issues in design and analysis. Dial. Clin. Neurosci. 2011;13(2):191-198

6. Moller H.-J. Effectiveness studies: advantages and dis- advantages. Dial. Clin. Neurosci. 2011;13(2):199-207

7. Patsopoulos N.F. A pragmatic view on pragmatic trials. Dial. Clin. Neurosci. 2011;13(2):217-224

8. Satlin A., Bodick N., Offen W.W., Renshaw P.F. Brain proton magnetic resonance spectroscopy (1H-MRS) in Alzheimer’s disease: changes after treatment with xanomeline, an M1 selective cholinergic agonist. Am. J. Psychiat. 1997;154(10):1459-1461

9. Barbagallo Sangiorgi G., Barbagallo M., Giordano M. et al. Alpha-Glycerophosphocholine in the mental recovery of cerebral ischemic attacks: An Italian multicenter clinical trial. Acad. Sci. 1994;717:253-269

10. Одинак М.М., Емелин А.Ю., Лобзин В.Ю., Колчева Ю.А. Терапия сосудистых когнитивных расстройств. РМЖ. 2009;20(359):1295-1297

11. Parnetti L. et al. Multicentre study of l-alpha-glyceryl- phosphorylcholine vs ST200 among patients with probable senile dementia of Alzheimer’s type. Drugs Aging. 1993; 3(2):159-164

12. Селезнева Н.Д., Колыхалов И.В., Герасимов Н.П. и др. Применение глиатилина для лечения деменций альцгей- меровского типа. Соц. клин. психиат. 1998;4:42-51

13. De Jesus Moreno Moreno M. Cognitive improvement in mild to moderate Alzheimer’s dementia after treatment with the 62 acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial. Clin. Ther. 2003;25(1):178-193

14. Leonard B.E. Pharmacother apy in the treatment of Alzheimer’s disease: an update. World Psychiat. 2004;3(2):84-89. Вопросы клинической и биологической психиатрии

15. Parnetti L., Amenta F., Gallai V. Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data. Mech. Ageing Dev. 2001;122(16):2041-2055

16. Parnetti L., Mignini F., Tomassoni D. et al. Cholinergic precursors in the treatment of cognitive impairment of vascular origin: ineffective approaches or need for re- evaluation? J. Neurol. Sci. 2007;257(1-2):264-269

17. Suchy J., Chan A., Shea T.B. Dietary supplementation with a combination of alpha-lipoic acid, acetyl-L-carnitine, glycerophosphocoline, docosahexaenoic acid, and phospha- tidylserine reduces oxidative damage to murine brain and improves cognitive performance. Nutr Res. ;29(1):70-74. doi: 10.1016/j.nutres.2008.11.004

18. Одинак М.М., Вознюк И.А. Современные средства лечения ишемического инсульта. Terra medica. 1999;2

19. Серегин В.И. Применение глиатилина и мексидола в интенсивной терапии тяжелого острого ишемического инсульта. Фарматека. 2006;5:24-25

20. Одинак М.М., Емелин А.Ю., Лобзин В.Ю., Колчева Ю.А. Терапия сосудистых когнитивных расстройств. РМЖ. 2009;20(359):1295-1297

21. Батышева Т.Т., Зайцев К.А., Камчатнов П.Р. и др. Эффективность применения альфосцерата холина (глиатилин) при легких когнитивных нарушениях сосудистого генеза. Журн. неврол. и психиат. им. С.С.Корсакова. 2011;8:29-32

22. Di Perri R., Coppola G., Ambrosio L.A. et al. A multicentre trial to evaluate the efficacy and tolerability of alpha- glycerylphosphorylcholine versus cytosine diphosphocholine in patients with vascular dementia. J. Int. Med. Res. 1991;19(4):330-341

23. Muratorio A., Bonuccelli U., Nuti A. et al. Нейротропный подход к лечению мультиинфарктной деменции с исполь- зованием холина альфосцерата. Международ. неврол. журн. 2014;3(65):10-17

24. Бачинская Н.Ю. Холинергическая стратегия в терапии когнитивных нарушений у пациентов пожилого и старческого возраста. Международ. неврол. журн. 2014;2(64)

25. Скоромец А.А., Шабалина И.Г., Бельцева Ю.А. Примене- ние холинотропных средств и постинсультная деменция у лиц пожилого и старческого возраста, переживших блокаду Ленинграда. Обозрен. психиат. и мед. психол. 2014;2:109-115

26. Amenta F., Carotenuto A., Fasanaro A.M. et al. The ASCOMALVA trial: association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer’s disease with cerebrovascular injury: interim results. J. Neurol. Sci. 2012;322(1-2):96- 101. doi: 10.1016/j.jns.2012.07.003

27. Amenta F., Carotenuto A., Fasanaro A.M. et al. The ASCOMALVA (Association between the Cholinesterase Inhibitor Donepezil and the Cholinergic Precursor Choline Alphoscerate in Alzheimer’s Disease) Trial: interim results after two years of treatment. J. Alzheimers Dis. 2014;42(Suppl. 3):S281-288. doi: 10.3233/JAD-140150

28. Tayebati S.K., Amenta F. Choline-containing phospholipids: relevance to brain functional pathways. Clin. Chem. Lab. Med. 2013;51(3):513-521. doi: 10.1515/cclm-2012-0559

29. Scapicchio P.L. Revisiting choline alphoscerate profile: a new, perspective, role in dementia? Int. J. Neurosci. - 2013;123(7):444-449. doi: 10.3109/00207454.2013.765870

30. Колыхалов И.В. Поведенческие и психопатологические симптомы при болезни Альцгеймера: эпидемиологические, психопатологические и нейробиологические аспекты. Психиатрия. 2015;3:74-84